# Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

> **NCT03173430** · EARLY_PHASE1 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT03173430
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-27
- **Primary completion:** 2019-01-28
- **Final completion:** 2019-01-28
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** PI decided to close study due to slow accrual.
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173430, "Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03173430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*